Regeneron Pharmaceuticals, Inc. (REGN) reported quarterly earnings of $9.47 per share on May 6, 2026, exceeding the Zacks Consensus Estimate of $8.52 per share and marking an earnings increase from $8.22 per share a year ago. The company’s revenue for the quarter totaled $3.61 billion, surpassing expectations by 4.88% and up from $3.03 billion in the same quarter last year.
Regeneron has consistently outperformed earnings estimates for the past four quarters. Despite this, shares have declined approximately 5.2% since the beginning of the year, compared to a 4.3% gain in the S&P 500. For the upcoming quarter, the consensus EPS estimate is $10.52 with projected revenues of $3.81 billion, and for the current fiscal year, expectations are set at $44.80 EPS and $15.51 billion in revenues.
As the biopharmaceutical company navigates a challenging market, investor sentiment will depend on management’s commentary during the earnings call and subsequent earnings estimate revisions. The current Zacks Rank for Regeneron is #3 (Hold), indicating expected performance in line with the market.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
